In an otherwise healthy adult with an uncomplicated urinary tract infection, is Macrobid (nitrofurantoin) effective against Proteus species and Streptococcus agalactiae (Group B Streptococcus)?

Macrobid (Nitrofurantoin) Is Not Effective Against Proteus Species or Streptococcus agalactiae

Nitrofurantoin should not be used for UTIs caused by Proteus species or Streptococcus agalactiae (Group B Streptococcus) because these organisms are intrinsically resistant to this antibiotic. 1

Intrinsic Resistance of Proteus Species

• Proteus species are inherently resistant to nitrofurantoin due to the organism's ability to produce urease, which alkalinizes urine and reduces nitrofurantoin activity; treatment failures with nitrofurantoin against Proteus are well-documented. 1

• In a retrospective study of hospitalized adults treated with nitrofurantoin for UTI, 5 of 8 treatment failures were attributed to intrinsically resistant uropathogens, specifically Proteus species. 1

• Nitrofurantoin demonstrates effective bactericidal activity only against susceptible organisms such as E. coli, Klebsiella spp., Enterobacter spp., Enterococcus spp., and Staphylococcus aureus—Proteus is explicitly excluded from this list. 2

Streptococcus agalactiae (Group B Streptococcus) Coverage

• Nitrofurantoin lacks reliable activity against Streptococcus agalactiae (GBS), which is not among the organisms for which nitrofurantoin is recommended in current treatment guidelines for uncomplicated UTI. 3, 4

• The 2011 IDSA/ESMID international guidelines recommend nitrofurantoin for uncomplicated cystitis caused by common uropathogens (E. coli, Klebsiella, Enterococcus) but do not list GBS as a target organism. 3

Appropriate Alternative Agents for Proteus and GBS UTIs

For Proteus Species UTI:

• Trimethoprim-sulfamethoxazole (TMP-SMX) 160/800 mg orally twice daily for 3 days is effective when the isolate is susceptible and local resistance is <20%. 3

• Fluoroquinolones (ciprofloxacin 250–500 mg twice daily or levofloxacin 750 mg once daily for 3 days) provide excellent coverage for Proteus species when susceptibility is confirmed. 3

• Oral cephalosporins (e.g., cefpodoxime, ceftibuten) for 3–7 days are acceptable alternatives, though they achieve lower efficacy (≈89% clinical cure) compared with fluoroquinolones or TMP-SMX. 3

For Streptococcus agalactiae (GBS) UTI:

• Amoxicillin 500 mg orally three times daily for 3–7 days provides reliable coverage for GBS and is safe in pregnancy. 4

• Amoxicillin-clavulanate 875/125 mg orally twice daily for 3–7 days is an alternative when broader coverage is needed. 3

• Cephalexin 500 mg orally four times daily for 7 days is effective against GBS when penicillin allergy is not present. 5

Clinical Decision Algorithm

1. Obtain urine culture with susceptibility testing before initiating therapy to identify the causative organism and guide targeted treatment. 3, 5

2. If Proteus species is identified:

   • First-line: TMP-SMX (if local resistance <20% and no recent exposure). 3
   • Second-line: Fluoroquinolone (if susceptible and local resistance <10%). 3
   • Third-line: Oral cephalosporin (if first-line agents contraindicated). 3

3. If Streptococcus agalactiae is identified:

   • First-line: Amoxicillin or amoxicillin-clavulanate. 4
   • Alternative: Cephalexin (if no penicillin allergy). 5

4. Do not prescribe nitrofurantoin empirically when Proteus or GBS is suspected based on clinical context (e.g., alkaline urine pH >9 suggests Proteus; pregnancy or recent GBS colonization suggests GBS). 1, 4

Critical Pitfalls to Avoid

• Do not continue nitrofurantoin if culture results reveal Proteus or GBS, as this will result in treatment failure and potential complications. 1

• Alkaline urine (pH >9) is a clinical clue for Proteus infection and should prompt selection of an alternative agent even before culture results are available. 1

• Do not use nitrofurantoin for complicated UTIs or upper-tract infections regardless of organism, as tissue penetration is insufficient. 3, 4